Screener
Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Interest Expense, Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Gain (loss) from short-term investments | 11,754 | 939 | 15,623 | (11,428) |
| Gain (loss) from change in fair value of equity-method investments and other investments | 35,727 | — | (13,502) | — |
| Interest income | 7,298 | 1,621 | 13,953 | 3,392 |
| Interest expense | (1,748) | (1,153) | (3,495) | (2,020) |
| Other non-operating expense, net | 2,682 | 1,372 | 1,507 | (1,129) |
| Total non-operating income (expenses), net | 55,713 | 2,779 | 14,086 | (11,185) |
| Income (loss) before income taxes | 64,304 | 11,223 | 40,045 | (38,957) |
| Income tax (expense) benefit | (15,796) | (6,376) | (4,882) | 1,353 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating?
- Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — interest expense, nonoperating of $1.75M in Q2 2026.
- How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating changed year-over-year?
- Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating increased by 51.6% year-over-year, from $1.15M to $1.75M.
- What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating has grown at a 37.9% compound annual growth rate (CAGR), from $1.8M to $4.72M.
- What does development and licensing of biopharmaceutical assets — interest expense, nonoperating mean?
- This metric represents the costs incurred on debt obligations and other financing arrangements that are classified as non-operating expenses for the segment. It measures the financial burden of the segment's capital structure and leverage. Investors monitor this to assess the impact of debt servicing on the segment's net profitability.
Ask your AI about Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude